| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
|
|
|
||||||
|
||||||||
Disorders of Iron Metabolism |
Department of Clinical Chemistry, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
Correspondence: Dorine W. Swinkels, Department of Clinical Chemistry 441, Radboud University Nijmegen Medical Centre, P.O. Box 9101 6500 HB Nijmegen, The Netherlands. E-mail: d.swinkels{at}akc.umcn.nl
Although iron is essential for living organisms to survive, its reactive properties require strict regulation in order to prevent toxic effects. Hepcidin, a liver produced peptide hormone, is thought to be the central regulator of body iron metabolism. Its production is mainly controlled by the erythropoietic activity of the bone-marrow, the amount of circulating and stored body iron, and inflammation. Recent reports, however, provide new hypotheses on how hepcidin might exert its regulatory function. Although hepcidin was first discovered in human urine and serum, most of our understanding of hepcidin regulation and action comes from in vitro and mice studies that often use hepcidin mRNA expression as a read out. The difficulties in carrying out studies in humans have mostly been due to the lack of suitable hepcidin assay. The recent development of assays to measure hepcidin in serum and urine has offered new opportunities to study hepcidin regulation in humans. However, for the moment, only a small number of laboratories are able to perform these assays. The aim of this review is to discuss insights into hepcidin regulation obtained from recent clinical studies in the light of findings from in vitro and mice studies. Ongoing studies in humans should provide us with more information on the etiology of iron metabolism disorders in order to create new therapeutic strategies and improve differential diagnosis protocols for these diseases.
Key words: hepcidin, iron.
This article has been cited by other articles:
|
|
 |
|
  J. J.C. Kroot, C. M.M. Laarakkers, E. H.J.M. Kemna, B. J. Biemond, and D. W. Swinkels Regulation of serum hepcidin levels in sickle cell disease Haematologica, June 1, 2009; 94(6): 885 - 887. [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Karl, H. R. Lieberman, S. J. Cable, K. W. Williams, E. L. Glickman, A. J. Young, and J. P. McClung Poor Iron Status Is Not Associated with Overweight or Overfat in Non-Obese Pre-Menopausal Women J. Am. Coll. Nutr., February 1, 2009; 28(1): 37 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M Frazer and G. J Anderson Hepcidin compared with prohepcidin: an absorbing story Am. J. Clinical Nutrition, February 1, 2009; 89(2): 475 - 476. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Melis, M. Cau, R. Congiu, G. Sole, S. Barella, A. Cao, M. Westerman, M. Cazzola, and R. Galanello A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron Haematologica, October 1, 2008; 93(10): 1473 - 1479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Kobold, T. Dulffer, M. Dangl, A. Escherich, M. Kubbies, R. Roddiger, and J. A. Wright Quantification of Hepcidin-25 in Human Serum by Isotope Dilution Micro-HPLC-Tandem Mass Spectrometry Clin. Chem., September 1, 2008; 54(9): 1584 - 1586. [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Swinkels and J. F. M. Wetzels Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease? Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2450 - 2453. [Full Text] [PDF]
|
|
|
|
|
|
K. S. Olsson and A. Norrby Comment to: Hepcidin: from discovery to differential diagnosis. Haematologica 2008; 93:90-7 Haematologica, June 1, 2008; 93(6): e51 - e51. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
